Tags

Type your tag names separated by a space and hit enter

Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
J Natl Cancer Inst. 2005 Apr 06; 97(7):542; author reply 542-3.JNCI

Authors

Yalcin B
No affiliation info available
Buyukcelik A
No affiliation info available
Yalcin S
No affiliation info available
Utkan G
No affiliation info available
Doruk H
No affiliation info available
Dogan M
No affiliation info available
Altan M
No affiliation info available

MeSH

Breast NeoplasmsConfounding Factors, EpidemiologicCyclooxygenase 2Double-Blind MethodDrug SynergismEnzyme InhibitorsFemaleHumansIncidenceMembrane ProteinsOsteoporosis, PostmenopausalProstaglandin-Endoperoxide SynthasesRaloxifene HydrochlorideRandomized Controlled Trials as TopicSelective Estrogen Receptor ModulatorsThromboembolismTreatment OutcomeUnited States

Pub Type(s)

Letter
Comment

Language

eng

PubMed ID

15812082

Citation

Yalcin, Bulent, et al. "Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene." Journal of the National Cancer Institute, vol. 97, no. 7, 2005, pp. 542; author reply 542-3.
Yalcin B, Buyukcelik A, Yalcin S, et al. Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2005;97(7):542; author reply 542-3.
Yalcin, B., Buyukcelik, A., Yalcin, S., Utkan, G., Doruk, H., Dogan, M., & Altan, M. (2005). Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Journal of the National Cancer Institute, 97(7), 542; author reply 542-3.
Yalcin B, et al. Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. J Natl Cancer Inst. 2005 Apr 6;97(7):542; author reply 542-3. PubMed PMID: 15812082.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. AU - Yalcin,Bulent, AU - Buyukcelik,Abdullah, AU - Yalcin,Samet, AU - Utkan,Gungor, AU - Doruk,Hatice, AU - Dogan,Mutlu, AU - Altan,Mehmet, PY - 2005/4/7/pubmed PY - 2005/4/13/medline PY - 2005/4/7/entrez SP - 542; author reply 542-3 JF - Journal of the National Cancer Institute JO - J Natl Cancer Inst VL - 97 IS - 7 SN - 1460-2105 UR - https://www.unboundmedicine.com/medline/citation/15812082/Re:_Continuing_outcomes_relevant_to_Evista:_breast_cancer_incidence_in_postmenopausal_osteoporotic_women_in_a_randomized_trial_of_raloxifene_ DB - PRIME DP - Unbound Medicine ER -